CAR T-cell therapy in MM: Updated Data and the Future

Data from the phase 3 AQUILA study support the FDA approval of subcutaneous daratumumab in this smoldering multiple myeloma population.

A panel of clinical pharmacists discussed strategies for mitigating toxicities across different multiple myeloma, lymphoma, and leukemia populations.

Investigators are currently assessing the antibody-drug conjugate HDP-101 as part of a phase 1/2a study.

Steven E. Finkelstein, MD, DABR, FACRO discuses how Prolaris distinguishes itself from other genomic biomarker platforms by providing uniquely actionable clinical information that quantifies the absolute benefit of androgen deprivation therapy when added to radiation therapy, offering clinicians a more precise tool for personalizing prostate cancer treatment strategies.

Investigators plan to present detailed findings from the MajesTEC-3 study at a future medical conference and share them with regulatory authorities.

The addition of comprehensive bridging radiotherapy to extramedullary disease sites before CAR T therapy may improve PFS outcomes in multiple myeloma.